Neurocrine Biosciences | NBIX - Operating Expenses


Neurocrine Biosciences reported $577.6M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Prothena USD 27.23M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Repligen USD 177.94M 1.82M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xoma USD 22.84M 1.67M Sep/2024